Real-world treatment pathways and outcomes in metastatic NSCLC across Spanish hospitals: Insights from the ECO-ARWEN study.
Abstract
716 Background: Real-world evidence can help evaluate whether advances in oncology care are being consistently translated into routine clinical practice. The rapid evolution of immunotherapy and targeted therapies has reshaped the management of metastatic non-small cell lung cancer (mNSCLC). However, the extent to which these advances are consistently implemented in routine clinical practice remains unclear. ECO-ARWEN is a multicenter Spanish real-world data initiative evaluating treatment patterns and outcomes across hospitals. Methods: We conduct a retrospective cohort study using hospital-based real-world data from six Spanish centers. Patients (≥18 years) with lung cancer treated between January 1, 2019, and December 31, 2023, were included and classified by stage at diagnosis. For patients with mNSCLC, treatment patterns were described by calendar year, treatment class, and line of therapy. OS was estimated from treatment initiation to death, and TTNT was evaluated by first-line treatment class. Results: Among 4,018 patients with NSCLC, 1,866 (46.4%) had metastatic disease, 1,647 (88.2%) received systemic treatment. Mean (SD) age was 67.8 (9.8) years, and 64.6% were male. Median OS was 17.0 months (95% CI, 15.4-18.1). Treatment pathways changed substantially over time, with a shift from chemotherapy alone toward immunotherapy-based and biomarker-driven strategies reflecting the adoption of novel therapies. By 2023, chemotherapy represented 21.3% of first-line treatments, while chemo-immunotherapy accounted for 53.3%, immunotherapy for 15.7%, and targeted therapy for 9.6%. Across the full study period, chemo-immunotherapy was the most common first-line class (37.8%), followed by chemotherapy (32.0%), immunotherapy (16.8%), and targeted therapy (7.3%). The most frequent regimen was platinum-pemetrexed-pembrolizumab (25.1%). Median TTNT was longest with targeted therapy (13.4 months), followed by immunotherapy (9.1 months), chemo-immunotherapy (7.9 months), and chemotherapy (6.2 months). Conclusions: In this multicenter real-world cohort, treatment patterns in mNSCLC evolved toward increased use of immunotherapy-based and targeted strategies, although substantial inter-treatment variability persists. Differences in TTNT across treatment classes and heterogeneous uptake of innovation highlight opportunities to benchmark and optimize quality of care. Ongoing expansion of ECO-ARWEN to additional centers will enable more robust assessment of inter-hospital variation and care standardization.